688, 185 may 19 announcement: the World Health Organization (who) disclosed on its official website on May 19 that the company’s recombinant novel coronavirus vaccine (adenovirus type 5 vector) kweisa was included in the “emergency use list” (Eul). The product is constructed by genetic engineering method. With replication defective human type 5 adenovirus as the vector, it can express the S antigen of novel coronavirus. It is intended to prevent diseases caused by novel coronavirus infection. At the same time, it does not contain preservatives, adjuvants and ingredients of animal origin. After the product is included in who Eul, the company still needs to conduct commercial negotiations with the intended countries on the future sales of the product. If the subsequent overseas countries increase the purchase and use of the product, it will have a certain positive impact on the performance of the listed company.
© China Stock Market News